medigraphic.com

2018, Number 5

<< Back Next >>

Cir Cir 2018; 86 (5)

Risk of recurrence and new malignant cutaneous neoplasms in Mexican subjects with basal cell carcinoma

Ruiz-González JF, Guevara-Gutiérrez E, Hernández-Torres M, Solís Ledesma G, Tlacuilo-Parra A

Language: Spanish
References: 24
Page: 417-422
PDF size: 233.56 Kb.


ABSTRACT

Introduction: Basal cell carcinoma (BCC) is the most common skin malignant neoplasm. Objective. Investigate the risk of recurrence and of new skin malignant neoplasms, after treatment of BCC. Method: Retrospective study. We examined the files of patients with histopathological diagnosis of primary BCC, between January 2007 and December 2009, and we investigate number of recurrences and their relationship with localization, treatment type, and histopathological variant, and the number of new skin malignant neoplasms. For analysis, we employed descriptive and inferential statistics; p ‹ 0.05 was considered significant. Results: A total of 397 patients, with an average follow-up of 4 1.5 years. Recurrences presented in 4%. Recurrences were related with longer time of evolution (36 vs. 32 months; p = 0.04) and treatment with destructive techniques (electrofulguration, cryosurgery or imiquimod; 31 vs. 4%; p ‹ 0.001). There was no relationship with localization, or the histopathological variant. The risk of developing a new malignant neoplasm was 25%; 66% corresponded to a new BCC and 30% to squamous cell carcinoma. Conclusions: Follow-up of patients with BCC should be conducted independently of their localization and histopathological variant, especially in patients with greater evolution time, principally with surgical techniques.


REFERENCES

  1. Lucas R, McMichael T, Smith W, Armstrong B. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069-80.

  2. Hernández-Zárate SI, Medina-Bojórquez A, López-Tello SAL, Alcalá-Pérez D. Epidemiología del cáncer de piel en pacientes de la Clínica de Dermato- oncología del Centro Dermatológico Dr. Ladislao de la Pascua. Estudio retrospectivo de los últimos ocho años. Dermatol Rev Mex. 2012;56:30-7.

  3. Gutiérrez VRM. Cáncer de piel. Rev Fac Med UNAM. 2003;46:166-71.

  4. Alfaro A, Castrejón L, Rodríguez OM. Cáncer de piel. Estudio epidemiológico a 10 años en derechohabientes del ISSSTE en Nuevo León. Dermatol Rev Mex. 2010;54:321-5.

  5. Holme S. Changing trends in non-melanoma skin cancer in South Wales, 1988-1998. Br J Dermatol. 2000;143:1224-9.

  6. Demers AA, Nugent Z, Mihalcioiu C, Wiseman MC, Kliewer EV. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol. 2005;53:320-8.

  7. Green A, Battistutta D, Hart V, Leslie D, Weedon D. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. Am J Epidemiol. 1996;144:1034-40.

  8. Saucedo RAP, Gutiérrez VRM, Medina BA. Cáncer de piel en el Centro Dermatológico Pascua. Estudio epidemiológico de 10 años. Dermatol Rev Mex. 2005;49:231-40.

  9. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013;133:1188‑96.

  10. Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol. 2006;47:1‑12.

  11. Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg. 2005;58:795‑805.

  12. Kuflik EG. Evidence-based review of the use of cryosurgery in treatment of basal cell carcinoma. Dermatol Surg. 2003;29 566-71.

  13. McLoone NM, Tolland J, Walsh M, Dolan OM. Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol. 2006;20:698-701.

  14. Marghoob A, Kopf AW, Bart RS, Sanfilippo L, Silverman MK, Lee P, et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol. 1993;28:22-8.

  15. Batra RS, Kelley LC. A risk scale for predicting extensive subclinical spread of nonmelanoma skin cancer. Dermatol Surg. 2002;28:107‑12.

  16. Rodríguez-Vigil T, Vázquez-López F, Pérez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol. 2007;56:91-5.

  17. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, García Díez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939-47.

  18. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157:S47-S51.

  19. Kricker A, Armstrong B, Hansen V, Watson A, Singh-Khaira G, Lecathelinais C, et al. Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients. J Am Acad Dermatol. 2014;70:456-64.

  20. Guía de Práctica Clínica de Prevención, Diagnóstico y Tratamiento del Carcinoma Basocelular. México: Secretaría de Salud; 2013.

  21. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9:1149-56.

  22. Telfer NR, Colver GB, Morton CA, British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159:35-48.

  23. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006;45:489-498.

  24. Chinem VP, Miot HA. Prevalence of actinic skin lesions in patients with basal cell carcinoma of the head: a case-control study. Rev Assoc Med Bras. 2011;58:188-96.




2020     |     www.medigraphic.com